July 10, 2023 4:52pm

However, expectations are for LPS (loss-per-share) Q2 earnings to incline while runways slip

Pre-open Indications: 2 Hits and 1 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed! 

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x- military officer, x-FBI, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +209.52 points (+0.62%), the S&P closed UP +10.58 points (+0.24%) while the Nasdaq closed UP +24.76 points (+0.18%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed up after being down and mixed for most of the session.

 

Friday (7/10) … RegMed Investors’ (RMi) pre-open: “resistance comes in many forms. Brace for the start of Q2 earnings season. “ https://www.regmedinvestors.com/articles/13036

 

Pre-open Indications: 2 Hits < Blueprint Medicine (BPMC -$0.73), Sage Therapeutics (SAGE +$1.56> and 1 Miss < Caribou Therapeutics (CRBU -$0.62)>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Monday’s advance/decline line opened positive at 26 up/ 8 down and 1 flat, stayed positive with 27 up/ 55 down and 2 flats at the mid-day, ending with a positive close of 25/7 and 3 flats
  • Friday’s advance/decline line opened positive at 24 up/ 9 down and 2 flats, stayed positive with 21 up/ 14 down and 0 flat at the mid-day, ending with a positive close of 24 incliners, 11 decliners and 0 flat

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +1.83% and the XBI was up +3%
  • Friday the IBB was down -0.85% and the XBI was up +0.11%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.23 point or +1.55% at 15.06
  • Friday was down -0.61point or -3.95% at 14.83

 

Closing Down (7 of 7):

  • Blueprint Medicine (BPMC -$0.73 after Friday’s +$0.32),
  • Caribou Therapeutics (CRBU -$0.62 after Friday’s +$1.32),
  • Ultragenyx (RARE -$0.40),
  • Mesoblast (MESO -$0.07),
  • Voyager Therapeutics (VYGR -$0.05 after Friday’s -$0.41),
  • Precigen (PGEN -$0.02),
  • Solid Biosciences (SLDB -$0.01)

Flat (3):

  • Biostage (OTCQN: BSTB),
  • Graphite BIO (GRPH),
  • Ionis Pharmaceuticals (IONS)

Closing Up (10 of 25):

  • Alnylam Pharmaceuticals (ALNY +$7.13 after Friday’s -$1.71),
  • Intellia Therapeutics (NTLA +$3.55 after Friday’s +$0.23),
  • CRISPR Therapeutics (CRSP +$3.29 after Friday’s +$0.35),
  • Sage Therapeutics (SAGE +$1.56 after Friday’s +$0.17),
  • Beam Therapeutics (BEAM +$1.56),
  • Vericel (VCEL +$1.20 after Friday’s -$0.97),
  • Verve Therapeutics (VERV +$1.19 after Friday’s +$0.10),
  • BioLife Solutions (BLFS +$0.92 after Friday’s -$0.20),
  • Prime Medicine (PRMC +$0.42 after Friday’s +$0.75),
  • Editas Medicine (EDIT +$0.41),

 

Q3/23 – July

  • Monday closed positive with 25 incliners, 7 decliners and 3 flats
  • Friday closed positive with 24 incliners, 11 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Trying to take a few days/sessions off but, all it should entail is fewer words -- never losing the impact of the daily action.

There's a lot of uncertainty right now about whether electronic trading and algorithms will react to share pricing!

The coming issue is Q2 reporting is weeks if not a month away.

 

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Unresolved issues affecting our perception of markets and the factors controlling them --- who is in CONTROL of our government as a dime sized coke bag was found in the West Wing of the White House, political investigation of the Bidens, future rate increases, the Ukraine war, Russia’s economic and political uncertainty and the major issue - recession - US and global could freezing investors' mood.

 

The top three (3) performing in the session:

·         Monday: Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP)

·         Friday: Caribou Biosciences (CRBU) - again, Prime Medicine (PRME) and Generation BIO (GBIO)

While The worst three (3) in the session:

·         Monday: Blueprint Medicine (BPMC), Caribou Biosciences (CRBU) and Ultragenyx Pharmaceuticals (RARE) - again

·         Friday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Ultragenyx Pharmaceuticals (RARE)

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues!

Monday closed flat with 7 shares traded after Friday closed down -$0.01, Thursday closed down -$0.01 with 100 shares traded, Thursday’s +$0.03 with 185 shares traded, Wednesday closed flat to $3.97 with 1 share traded and last Tuesday was a holiday, <3-month average = 763 shares>

·         Question: is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!

·         How many chairman, executives, board and audit members, CMOs, CFOs and employees has BSTG EATEN since it spun out of Harvard BIO (HBIO) which STILL carries the financial (millions) burden from its spin-out by a BSTG chairman as he “shuffled” debt from individual named management!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.